研究
研究業績・論文発表
血液グループ 論文
Rai S, Duns G, Frontzek F, Wong JCH, Yin Y, Li MY, Kishida M, Fujisawa M, Healy S, Viganò E, Jiang A, Woolcock B, Telenius A, Ben-Neriah S, Meissner B, Boyle M, Nakamura H, O Brien L, Cassidy C, Lytle A, Farinha P, Slack GW, Hilton LK, Morin RD, Venturutti L, Aoki T, Wretham N, Bush JW, Evgin L, Savage KJ, Scott DW, Steidl C.
Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma
Blood 2025 in press
Yoshimitsu M, Choi I, Kusumoto S, Shimokawa M, Utsunomiya A, Suehiro Y Dr, Hidaka T, Nosaka K, Sasaki H, Rai S, Tamura S, Owatari S, Koh KR, Nakamura D, Tokunaga M, Sekine M, Sakamoto Y, Inagaki H, Ishida T, Ishitsuka K.
A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma
Blood 2025
Okayama Y, Takakuwa T, Shimura Y, Imada K, Kosugi S, Hotta M, Fuchida SI, Tanaka H, Uoshima N, Yoshihara S, Kanda J, Shibayama H, Fukushima K, Ohta K, Yagi H, Ito T, Shimazaki C, Matsumura I, Takaori-Kondo A, Hosen N, Hino M, Kuroda J.
Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum
Hematology 2025
Munakata W, Kumode T, Goto H, Fukuhara N, Shimoyama T, Takeuchi M, Kawakita T, Kubo K, Sawa M, Uchida T, Mishima Y, Ichii M, Hanaya M, Matsumoto A, Kuriki M, Seike T, Izutsu K, Ishizawa K.
A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study
Br J Haematol 2025
Lee JW, Jang JH, Yamazaki H, Sawa M, Kizaki M, Tomiyama Y, Nagafuji K, Usuki K, Gau JP, Morita Y, Tang JL, Chang H, Noshiro M, Matsuda A, Ozawa K, Mitani K, Kanda Y, Nakao S.
Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia
Blood Adv 2025
Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F.
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study
Lancet Haematol. 2024
Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Maruyama D, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Kato H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K.
Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results
Haematologica 2024
Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, Tateishi U, Miyamoto T, Matsuda Y, Ishikawa J, Rai S, Takahashi T, Yamauchi T, Matsumura I, Akashi K, Kanakura Y, Suzumiya J.
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial
Int J Hematol. 2024
Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Abe M, Hojo S, Nakanishi T, Rai S.
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study
Int J Hematol. 2024
Matsumura I, Ohtake S, Atsuta Y, Kurata M, Minami Y, Takahashi N, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Ono T, Okada M, Tauchi T, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Asou N, Naoe T, Kiyoi H, Miyazaki Y.
Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study.
Blood Adv. 2024
Hayakawa F, Mori N, Imai K, Yokoyama Y, Katsuoka Y, Saito T, Murayama T, Yamazaki E, Sato S, Atsuta Y, Ishikawa Y, Sakaida E, Hatta Y, Matsumura I, Miyazaki Y, Kiyoi H; Japan Adult Leukemia Study Group (JALSG).
Nelarabine-combined chemotherapy improves outcome of T-cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T-ALL213-O.
Cancer Sci. 2025
Fukui-Morimoto A, Serizawa K, Fujimoto K, Hanamoto A, Iwata Y, Kakutani H, Kumode T, Hirase C, Morita Y, Tatsumi Y, Hanamoto H, Tanaka H, Matsumura I.
CD34+ and CD34- MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34+ MM cells.
Int J Hematol. 2025
Kondo T, Matsuki E, Takaku T, Watanabe N, Yoshida C, Okada M, Murai K, Kodama T, Takahashi N, Kimura S, Matsumura I; Preg‐CML/Japan Study Investigators.
Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Cancer 2024
Sugimoto Y, Nagaharu K, Ohya E, Ohishi K, Tawara I, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Saito AM, Shimoda K, Kurokawa T, Tomita A, Edahiro Y, Hashimoto Y, Kiyoi H, Akashi K, Matsumura I, Takenaka K, Komatsu N.
Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan.
Int J Hematol. 2024
Shimoda K, Komatsu N, Matsumura I, Ikeda K, Hino M, Hidaka M, Maeda Y, Kondo T, Fujisaki T, Shoshi K, Azuma K, Fukushima R, Kawashima J, Kosugi H.
Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial.
Int J Hematol. 2024
Nagaharu K, Ohya E, Edahiro Y, Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Saito AM, Shimoda K, Kurokawa T, Tomita A, Kiyoi H, Akashi K, Matsumura I, Takenaka K, Komatsu N, Ohishi K, Tawara I, Sugimoto Y.
Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis.
Ann Hematol. 2024
Minami Y, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, Kubo K, Goto T, Kirito K, Maki A, Aoki M, Dawson MK, Matsumura I.
Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
Int J Hematol. 2024
Shimazu Y, Kanda J, Onda Y, Fuchida SI, Ohta K, Shimura Y, Kosugi S, Yamamura R, Matsuda M, Hanamoto H, Adachi Y, Anzai N, Hotta M, Fukushima K, Yagi H, Yoshihara S, Tanaka Y, Takakuwa T, Tanaka H, Shibayama H, Uoshima N, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M.
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Cancer Immunol Immunother. 2024
Kondo A, Tanaka H, Rai S, Shima H, Matsumura I, Watanabe T.
Depletion of Ppp6c in hematopoietic and vascular endothelial cells causes embryonic lethality and decreased hematopoietic potential.
Exp Hematol. 2024
Kondo A, Tanaka H, Rai S, Shima H, Matsumura I, Watanabe T.
Depletion of Ppp6c in hematopoietic and vascular endothelial cells causes embryonic lethality and decreased hematopoietic potential.
Exp Hematol. 2024
膠原病グループ 論文
Ashida C, Nozaki Y, Li J, Akazawa H, Kishimoto K, Kinoshita K, Matsumura I.
Urinary Kim-1 Correlates with Interstitial Nephritis Activity in Patients with Microscopic Polyangiitis
Curr Issues Mol Biol 2025
Nozaki Y, Kishimoto K, Tomita D, Itami T, Ashida C, Kinoshita K,Matsumura I.
Utility of the GerdQ questionnaire in detecting gastroesophageal symptoms with RA patients
BMC Rheumatol 2024
Nozaki Y, Akiba H, Akazawa H, Yamazawa H, Ishimura K, Kinoshita K, Matsumura I.
Inhibition of the TIM-1 and -3 signaling pathway ameliorates disease in a murine model of rheumatoid arthritis
Clin Exp Immunol 2024
Akazawa H, Nozaki Y, Yamazawa H, Ishimura K, Ashida C, Okada A, Kinoshita K, Matsumura I.
Blockade of IL-18Rα-mediated signaling pathway exacerbates neutrophil infiltration in imiquimod-induced psoriasis murine model.
Front Med (Lausanne). 2023 Oct 27
Yuji Nozaki, Motohiro Oribe, Daisuke Tomita, Tetsu Itami, Shinya Hayashi, Toshihisa Maeda, Koji Fukuda, Ryosuke Kuroda, Keiko Funahashi, Tsukasa Matsubara, Koji Kinoshita, Itaru Matsumura
Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching
Modan Rheumatology 2022 June13
Nozaki Y, Kotani T, Takeuchi T, Hidaka T, Miyake H, Hatta K, Kurosawa Y, Sudo M, Ito S, Kinoshita K, Matsumura I
The Impact of Early Optimization of Infliximab Blood Concentrations >1 μg/mL on Therapeutic Effectiveness in Rheumatoid Arthritis.
Front Biosci (Landmark Ed) 2023 Apr 6
Jinhai Li, Yuji Nozaki , Hiroki Akazawa, Kazuya Kishimoto, Koji Kinoshita and Itaru Matsumura
Deletion of Antigen-Presenting Cells in Lipopolysaccharide-Induced Acute Kidney Injury (AKI) Affects the Exacerbation and Repair in AKI
Current Issues in Molecular Biology 2022 in press
Yuji Nozaki, Motohiro Oribe, Daisuke Tomita, Tetsu Itami, Shinya Hayashi, Toshihisa Maeda, Koji Fukuda, Ryosuke Kuroda, Keiko Funahashi, Tsukasa Matsubara, Koji Kinoshita, Itaru Matsumura
Iguratimod Versus Salazosulfapyridine in Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate: Adjusted with Propensity Score Matching
Mod Rheumatol 2022 Jun 13
Toshihiko Shiga, Yuji Nozaki, Daisuke Tomita, Kazuya Kishimoto, Yasuaki Hirooka, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura.
Usefulness of Interleukin-18 as a Diagnostic Biomarker to Differentiate Adult-Onset Still's Disease With/Without Macrophage Activation Syndrome From Other Secondary Hemophagocytic Lymphohistiocytosis in Adults
Front Immunol.2021
Akinori Okada, Yuji Nozaki, Shinya Rai, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura.
Antiretroviral Therapy Improves Acquired Immunodeficiency Syndrome with Systemic Lupus Erythematosus
Life 2021